GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Median PS Value

INMB (INmune Bio) Median PS Value : $0.00 (As of Dec. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. INmune Bio's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.003. INmune Bio's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-12-16), INmune Bio's share price is $4.75. INmune Bio's Median PS Value is $0.00. Therefore, INmune Bio's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for INmune Bio's Median PS Value or its related term are showing as below:

INMB's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.7
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

INmune Bio Median PS Value Historical Data

The historical data trend for INmune Bio's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Median PS Value Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

INmune Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of INmune Bio's Median PS Value

For the Biotechnology subindustry, INmune Bio's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where INmune Bio's Price-to-Median-PS-Value falls into.



INmune Bio Median PS Value Calculation

INmune Bio's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.003*0
=0.00

10-Year Median PS Ratio is 0.
INmune Bio's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INmune Bio  (NAS:INMB) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

INmune Bio's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=4.75/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INmune Bio Median PS Value Related Terms

Thank you for viewing the detailed overview of INmune Bio's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016